Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study - van Vollenhoven, R F; Hahn, B H; Tsokos, G C (Lancet, 2018)
et al.